Bristol Myers Squibb, Pfizer Announce Direct-to-patient Option For Eliquis

Bristol Myers Squibb and Pfizer have launched a direct-to-patient purchasing option for their co-developed blood thinner, Eliquis, effective September 8, offering eligible U.S. patients a discount exceeding 40%. This strategic move, aimed at enhancing patient access and affordability for a drug prescribed to over 15 million Americans and credited with significant healthcare cost savings, represents a notable shift in pharmaceutical distribution and pricing models.

Analysis

Bristol Myers Squibb (BMY) and Pfizer (PFE) are launching a direct-to-patient purchasing program for their blockbuster blood thinner, Eliquis, providing a significant discount of over 40% to eligible U.S. patients. This strategic shift in distribution, effective September 8, aims to enhance patient access and affordability for a drug already prescribed to over 15 million Americans. By bypassing traditional intermediaries, the companies may be seeking to protect market share, improve net pricing, and respond proactively to pricing pressures within the U.S. healthcare system. The move is framed by the drug's established value proposition, with BMY citing an estimated $3 billion in healthcare cost savings for every 100,000 patients treated due to reduced hospitalizations. The high positive sentiment scores for both BMY and PFE (0.7) indicate that the market views this as a shrewd maneuver to solidify the franchise's long-term position.

Key Decisions for Investors

• Investors should view this direct-to-patient initiative as a defensive strategy to protect Eliquis's revenue stream against pricing pressures and future competition; monitor prescription volume data after the September 8 launch to assess its effectiveness.
• Consider the potential impact on margins, as the over 40% discount could be offset by reduced rebate payments to pharmacy benefit managers, potentially improving net revenue per prescription sold through this channel.
• This move could signal a broader industry trend towards direct-to-consumer models for established drugs, so assess portfolio holdings for other pharmaceutical companies with blockbuster products that might adopt a similar strategy.